That's correct and I assume there will ultimately be more margin in the product (than GSK makes on Relenza prior to royalties) for the above reasons.
NVA Nova locks in NASDAQ US market listing at a value of only US$3.3M as ASX gets quieter and quieter
MND Monadelphous inks $200M contract with Woodside to help build Pluto LNG – but will it make Scarborough cheaper?